291 related articles for article (PubMed ID: 25944318)
21. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
22. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
[TBL] [Abstract][Full Text] [Related]
23. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
[TBL] [Abstract][Full Text] [Related]
24. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.
Malherbe G; Steel HC; Cassol S; de Oliveira T; Seebregts CJ; Anderson R; Cassol E; Rossouw TM
Mediators Inflamm; 2014; 2014():198413. PubMed ID: 24808634
[TBL] [Abstract][Full Text] [Related]
25. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
[TBL] [Abstract][Full Text] [Related]
26. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.
Laanani M; Ghosn J; Essat A; Melard A; Seng R; Gousset M; Panjo H; Mortier E; Girard PM; Goujard C; Meyer L; Rouzioux C;
Clin Infect Dis; 2015 Jun; 60(11):1715-21. PubMed ID: 25737374
[TBL] [Abstract][Full Text] [Related]
27. The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection.
O'Halloran JA; Dunne E; Gurwith M; Lambert JS; Sheehan GJ; Feeney ER; Pozniak A; Reiss P; Kenny D; Mallon P
HIV Med; 2015 Nov; 16(10):608-19. PubMed ID: 26111187
[TBL] [Abstract][Full Text] [Related]
28. The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women.
Lurain NS; Hanson BA; Hotton AL; Weber KM; Cohen MH; Landay AL
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):134-43. PubMed ID: 26422187
[TBL] [Abstract][Full Text] [Related]
29. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy.
Conley LJ; Bush TJ; Rupert AW; Sereti I; Patel P; Brooks JT; Baker JV;
AIDS; 2015 Oct; 29(16):2201-7. PubMed ID: 26544583
[TBL] [Abstract][Full Text] [Related]
30. The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.
Yin X; Wang Z; Wu T; Ma M; Zhang Z; Chu Z; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
J Transl Med; 2019 Dec; 17(1):417. PubMed ID: 31836011
[TBL] [Abstract][Full Text] [Related]
31. Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients.
Noel N; Boufassa F; Lécuroux C; Saez-Cirion A; Bourgeois C; Dunyach-Remy C; Goujard C; Rouzioux C; Meyer L; Pancino G; Venet A; Lambotte O;
AIDS; 2014 Feb; 28(4):467-76. PubMed ID: 24378753
[TBL] [Abstract][Full Text] [Related]
32. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
[TBL] [Abstract][Full Text] [Related]
33. CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy.
Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M
Antivir Ther; 2014; 19(4):429-33. PubMed ID: 24430489
[TBL] [Abstract][Full Text] [Related]
34. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
[TBL] [Abstract][Full Text] [Related]
35. Increased monocyte activation with age among HIV-infected long term non-progressor children: implications for early treatment initiation.
D'Souza RR; Gopalan BP; Rajnala N; Phetsouphanh C; Shet A
HIV Med; 2019 Sep; 20(8):513-522. PubMed ID: 31131542
[TBL] [Abstract][Full Text] [Related]
36. Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.
Mathad JS; Gupte N; Balagopal A; Asmuth D; Hakim J; Santos B; Riviere C; Hosseinipour M; Sugandhavesa P; Infante R; Pillay S; Cardoso SW; Mwelase N; Pawar J; Berendes S; Kumarasamy N; Andrade BB; Campbell TB; Currier JS; Cohn SE; Gupta A;
J Acquir Immune Defic Syndr; 2016 Oct; 73(2):123-9. PubMed ID: 27258230
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of combination antiretroviral therapy in HIV type 1-infected patients treated in Curaçao compared with Antillean, Surinam, and Dutch HIV type 1-infected patients treated in The Netherlands.
Hermanides HS; Gras L; Winkel CN; Gerstenbluth I; van Sighem A; de Wolf F; Duits AJ
AIDS Res Hum Retroviruses; 2011 Jun; 27(6):605-12. PubMed ID: 21155654
[TBL] [Abstract][Full Text] [Related]
38. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
[TBL] [Abstract][Full Text] [Related]
39. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
40. Plasma IP-10 Is Increased in Immunological NonResponders and Associated With Activated Regulatory T Cells and Persisting Low CD4 Counts.
Stiksrud B; Lorvik KB; Kvale D; Mollnes TE; Ueland PM; Trøseid M; Taskén K; Dyrhol-Riise AM
J Acquir Immune Defic Syndr; 2016 Oct; 73(2):138-48. PubMed ID: 27632144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
